Deficiencia de 3-beta-hidroxiesteroide deshidrogenasa: una causa rara de hiperplasia adrenal congénita / 3-beta-hydroxysteroid dehydrogenase deficiency: a rare cause of congenital adrenal hyperplasia

Resumen: la hiperplasia adrenal congénita corresponde a un grupo de enfermedades heredadas con defectos enzimáticos que pueden comprometer la biosíntesis del cortisol. La deficiencia de la enzima 3β-hidroxiesteroide deshidrogenasa tipo 2 es una causa rara de este defecto en la que el desarrollo genital masculino se encuentra alterado y presenta una virilización leve en las mujeres afectadas. En humanos se han descrito dos isoenzimas, la tipo I y la tipo II, codificadas por los genes HSD3B1 y HSD3B2, respectivamente, con una distribución tisular específica.Los programas de tamización de la hiperplasia adrenal congénita reportan elevación paradójica de la 17-hidroxiprogesterona secundaria al efecto periférico de la 3β-hidroxiesteroide deshidrogenasa tipo 1, isoenzima de la 3β-hidroxiesteroide deshidrogenasa tipo 2, que tiene una constante de Michaelis menor con el sustrato.A pesar de la baja prevalencia el estudio de este defecto ha tenido importantes avances en cuanto a la información molecular y el diagnóstico hormonal, datos que han sido respaldados por la identificación de la alteración genética y han disminuido la posibilidad del sobrediagnóstico; evento que se estaba presentado frecuentemente con los puntos de cortes establecidos inicialmente para el diagnósticode la enfermedad, sobre todo en sus formas leves.

Abstract: the congenital adrenal hyperplasia corresponds to a group of inherited diseases with enzyme defects that alter the cortisol biosynthesis. The 3β-hydroxysteroid dehydrogenase type 2 deficiency is a rare cause of this defect, where the male genital development is altered but little virilization in affected women is present. In humans two isoenzymes have been described, type I and type II, coded by HSD3B2 and HSD3B1 genes, respectively, and with specific tissuedistribution. The screening programs to congenital adrenal hyperplasia report paradoxical elevation of 17-hydroxyprogesterone secondary to peripheral effect of 3β-hydroxysteroid dehydrogenase type 1, an isoenzyme of 3β-hydroxysteroid dehydrogenase type 2. Type 1 has a lower Michaelis constant with the substrate; additional condition that relates with the paradoxical effect of the 17-hydroxyprogesterone.Besides the low prevalence, the study of this defect has had important progress about molecular information and hormonal diagnosis, data that has been confirmed with the identification of genetic alteration in the described gene, reducing the possibility of overdiagnosis; an event that was showing frequently with the initially cut-point stablished especially for milder forms of the disease.

A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome.

Human monogenic pain syndromes have provided important insights into the molecular mechanisms that underlie normal and pathological pain states. We describe an autosomal-dominant familial episodic pain syndrome characterized by episodes of debilitating upper body pain, triggered by fasting and physical stress. Linkage and haplotype analysis mapped this phenotype to a 25 cM region on chromosome 8q12-8q13. Candidate gene sequencing identified a point mutation (N855S) in the S4 transmembrane segment of TRPA1, a key sensor for environmental irritants. The mutant channel showed a normal pharmacological profile but altered biophysical properties, with a 5-fold increase in inward current on activation at normal resting potentials. Quantitative sensory testing demonstrated normal baseline sensory thresholds but an enhanced secondary hyperalgesia to punctate stimuli on treatment with mustard oil. TRPA1 antagonists inhibit the mutant channel, promising a useful therapy for this disorder. Our findings provide evidence that variation in the TRPA1 gene can alter pain perception in humans.